Literature DB >> 12191609

Designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis.

Christine Gould1, Chung F Wong.   

Abstract

Protein kinases are important targets for designing therapeutic drugs. We describe here a computational approach to extend the usefulness of a single protein-inhibitor structure in aiding the design of protein kinase inhibitors. This approach is based on using sensitivity analysis to identify the most significant functional groups of a lead compound in accounting for binding affinity and on using comparative sequence/structure analysis to examine whether these functional groups would present specificity. A sensitivity analysis study is similar to genetic or chemical modification experiments in which specific features of a lead compound are modified to examine whether they affect properties such as binding affinity. In this study, the binding affinity was estimated by using an implicit-solvent model in which the electrostatic contributions were obtained by solving the Poisson equation, and the hydrophobic effects were accounted for by using surface-area-dependent terms. The comparative sequence/structure analysis involves the study of the amino acid distributions of a large number of protein kinases (384 in this study) near the ligand-binding sites. This analysis provides useful guiding principles for designing specific inhibitors targeted towards a particular kinase. Here, we illustrate the utility of these computational approaches by applying them to identify the determinants of the recognition between the protein kinase A and two of its inhibitors. One inhibitor, balanol, binds to the ATP-binding pocket. The other, protein kinase inhibitor, binds to the substrate-binding site. These analyses have helped to construct pharmacophore models for mining new drug leads from small-molecule libraries and for suggesting how a lead compound or a peptide inhibitor may be modified to generate selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191609     DOI: 10.1016/s0163-7258(02)00186-9

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  5 in total

1.  Functional anthology of intrinsic disorder. 3. Ligands, post-translational modifications, and diseases associated with intrinsically disordered proteins.

Authors:  Hongbo Xie; Slobodan Vucetic; Lilia M Iakoucheva; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  J Proteome Res       Date:  2007-03-29       Impact factor: 4.466

2.  A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.

Authors:  Jans H Alzate-Morales; Renato Contreras; Alejandro Soriano; Iñaki Tuñon; Estanislao Silla
Journal:  Biophys J       Date:  2006-11-03       Impact factor: 4.033

3.  Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes.

Authors:  Y Anis; O Leshem; H Reuveni; I Wexler; R Ben Sasson; B Yahalom; M Laster; I Raz; S Ben Sasson; E Shafrir; E Ziv
Journal:  Diabetologia       Date:  2004-07-03       Impact factor: 10.122

4.  The importance of intrinsic disorder for protein phosphorylation.

Authors:  Lilia M Iakoucheva; Predrag Radivojac; Celeste J Brown; Timothy R O'Connor; Jason G Sikes; Zoran Obradovic; A Keith Dunker
Journal:  Nucleic Acids Res       Date:  2004-02-11       Impact factor: 16.971

5.  Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.

Authors:  Megan L Peach; Nelly Tan; Sarah J Choyke; Alessio Giubellino; Gagani Athauda; Terrence R Burke; Marc C Nicklaus; Donald P Bottaro
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.